ID NOW™

Simple, fast and accurate with molecular results for COVID-19, Flu, RSV and Strep A

ID NOW™

Simple, fast and accurate with molecular results for COVID-19, Flu, RSV and Strep A

ID NOW™
COVID-19

Detects Sars-CoV-2
in 13 minutes or less1

ID NOW™ 
INFLUENZA A & B 2

Positive results in as few as 5 minutes2

ID NOW™
RSV

Results in
13 minutes or less

ID NOW™
STREP A 2

The fastest Strep A test – positive results in as few as 2 minutes3

ID NOW™
COVID-19

Detects Sars-CoV-2
in 13 minutes or less1

ID NOW™ 
INFLUENZA A & B 2

Positive results in as few as 5 minutes2

ID NOW™
RSV

Results in
13 minutes or less

ID NOW™
STREP A 2

The fastest Strep A test – positive results in as few as 2 minutes3

CONTACT US TO LEARN MORE

EXTRAORDINARY TECHNOLOGY

ID NOW™ is the fastest point-of-care
molecular platform on the market.4
 

ID NOW™ utilises proven isothermal molecular technology in an intuitive platform, providing the fastest, highly sensitive molecular results in the market at 2 to 13 minutes.4

LEARN MORE IN THIS ANIMATION

Molecular technology PCR ID NOW™
Target DNA/RNA DNA/RNA
Common detection method Molecular beacon Molecular beacon
Amplification Yes Yes
Method to open DNA Heat Enzyme
Requires thermocycling Yes No
Time to results 15 minutes-hours ≤13 minutes

EXTRAORDINARY TECHNOLOGY

ID NOW™ is the fastest point-of-care molecular platform on the market.4
 

ID NOW™ utilises proven isothermal molecular technology in an intuitive platform, providing the fastest, highly sensitive molecular results in the market at 2 to 13 minutes.4

Molecular technology PCR ID NOW™
Target DNA/RNA DNA/ RNA
Common detection method Molecular beacon Molecular beacon
Amplification Yes Yes
Method to open DNA Heat Enzyme
Requires thermocycling Yes No
Time to results 15 minutes-hours ≤13 minutes

Learn more in this animation

TIMELY RESULTS.
TIMELY DECISIONS.

TIMELY RESULTS.

TIMELY DECISIONS.

OPTIMISE WORKFLOW AND PATIENT THROUGHPUT

Shorten wait times and length of stay.5,6 Median patient visit time is 15.7 minutes7

EFFICIENT USE OF ISOLATION RESOURCES AND PROCEDURES

Reduce hospital infection and outbreak rates8

APPROPRIATE USE OF OTHER TESTING

Reduce unnecessary imaging, blood and urine cultures, etc.9,10

APPROPRIATE ADMISSIONS

Reduce unnecessary admissions and improve bed management6

EFFICIENT USE OF TESTING RESOURCES

Faster time to results may lead to shorter operational time and instrumentation needed 

ANTIBIOTIC STEWARDSHIP

Decrease unnecessary
antibiotic use.9-11
Reduce adverse drug reactions5

DESIGNED FOR MULTIPLE SETTINGS THAT IMPACT PATIENT CARE

EASY TO USE

  • Small and portable. Maximises bench space and can be used at the point of care

  • Visual touchscreen interface with step-by-step instructions

  • Automated on-screen results eliminate all subjectivity and interpretation errors

  • Colour-coded test consumables to guide the user

  • Out-of-the-box connectivity to industry-leading open-platform connectivity solutions

LEARN MORE IN THIS ANIMATION

INCREASE THE LIKELIHOOD OF DETECTION 

  • Conventional non-molecular methods have suboptimal limits of detection

  • Samples with low viral/bacterial loads could result in a false negative result

  • Even when starting with only a few hundred viruses or bacteria, ID NOW™ amplifies the sample up to a trillion times!

  • Revolutionary molecular amplification increases the likelihood of detection, and may compensate for suboptimal sample collection

DESIGNED FOR MULTIPLE SETTINGS THAT IMPACT PATINET CARE

Easy to use

  • Small and portable. Maximises bench space and can be used at the point of care

  • Visual touchscreen interface with step-by-step instructions

  • Automated on-screen results eliminate all subjectivity and interpretation errors

  • Color-coded test consumables to guide the user

  • Out-of-the-box connectivity to industry-leading open-platform connectivity solutions

Learn more in this animation

Increase the likelihood
of detection 

  • Conventional non-molecular methods have suboptimal limits of detection

  • Samples with low viral/bacterial loads could result in a false negative result

  • Even when starting with only a few hundred viruses or bacteria, ID NOW™ amplifies the sample up to a trillion times!

  • Revolutionary molecular amplification increases the likelihood of detection, and may compensate for suboptimal sample collection

ID NOW™ COVID-19

Detects SARS-CoV-2 in
13 minutes or less1

  • Molecular COVID-19 test results in minutes enable immediate clinical decisions during the first patient visit

  • Easy to use platform designed for point of care use in a variety of healthcare settings

  • Direct sample types include:

    • Throat swab

    • Nasal swab

    • Nasopharyngeal swab

ID NOW™ COVID-19

Detects SARS-CoV-2 in
13 minutes or less1

  • Molecular COVID-19 test results in minutes enable immediate clinical decisions during the first patient visit

  • Easy to use platform designed for point of care use in a variety of healthcare settings

  • Direct sample types include:

    • Throat swab

    • Nasal swab

    • Nasopharyngeal swab

ID NOW™ INFLUENZA

A & B 2

The fastest molecular flu test just got faster and even better 

  • Now with early detection – positive results in as few as 5 minutes2

  • Detects up to 42% more true positives than rapid antigen detection tests12

  • Room temperature storage

ID NOW™
INFLUENZA A & B 2

The fastest molecular flu test just got faster and even better

  • Now with early detection – positive results in as few as 5 minutes2

  • Detects up to 42% more true positives than rapid antigen detection tests12

  • Room temperature storage

ID NOW™ RSV

The fastest RSV results when it matters most.

  • Actionable results in 13 minutes or less

  • 25% more truse positive than rapid antigen detection tests10,13

  • Room temperature storage

ID NOW™ RSV

The fastest RSV results when it matters most.

  • Actionable results in 13 minutes or less

  • 25% more truse positive than rapid antigen detection tests10,13

  • Room temperature storage

ID NOW™ STREP A2

Now the fastest Strep A test without the need for culture confirmation

  • The fastest Strep A test – positive results in as few as 2 minutes3

  • Enhanced molecular sensitivity eliminates the need for culture confirmation of negative result8

  • Nearly 90% fewer false negatives than rapid antigen detection tests8,14*

 
*Based on the reported sensitivities of RADTs and ID NOW Strep A 2

ID NOW™ STREP A2

Now the fastest Strep A test without the need for culture confirmation

  • The fastest Strep A test – positive results in as few as 2 minutes3

  • Enhanced molecular sensitivity eliminates the need for culture confirmation of negative result9

  • Nearly 90% fewer false negatives than rapid antigen detection tests8,14*

 
*Based on the reported sensitivities of RADTs and ID NOW Strep A 2

References

1. Internal clinical data, held on file. 
2. Moore N, et al. Evaluation of the Alere™ i Influenza A & B 2 Assay. 2018 ASM Clinical Virology Symposium, West Palm Beach, FL. Poster.
3. ID NOW™ Strep A 2 clinical trial data, held on file.
4. Abbott Press Release: Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results.
5. Barenfager J, et al. Clinical and Financial Benefits of Rapid Detection of Respiratory Viruses: an Outcomes Study. J Clin Microbiol. 2000;38(8):2824-2828.
6. Mills JM, et al. Rapid testing for respiratory syncytial virus in a paediatric emergency department: benefits for infection control and bed management. Journal of Hospital Infection. 2011;77:248-251.
7. Tai-Seale M, et al. Time Allocation in Primary Care Office Visits. Health Serv Res. 2007;42(5):1871-1894.
8. ID NOW™ Strep A 2 Product Insert.
9. Mackie PLK, et al. Evaluation of an acute point-of-care system screening for respiratory syncytial virus infection. Journal of Hospital Infection. 2001;48(1):66-71.
10. Chartrand C, et al. Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis. J Clin Microbiol. 2015;53(12):3738-3749.
11. Bonner AB, et al. Impact of the Rapid Diagnosis of Influenza on Physician Decision-Making and Patient Management in the Pediatric ED: Results of a Randomized, Prospective, Controlled Trial. Pediatrics. 2003;112(2):363-367. 
12. Chartrand C, et al, Accuracy of Rapid Influenza Diagnostic Tests A Meta-analysis. Ann Intern Med. 2012;156(7);500-511.
13. ID NOW™ RSV Product Insert.
14. Cohen JF, et al. Rapid antigen detection test for group A streptococcus in children with pharyngitis. Cochrane Database Syst Rev. 2016,7(7):CD010502.

Contact us

©2021 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.  Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. WEBCODE-1591 03/21.

References

1. Internal clinical data, held on file. 
2. Moore N, et al. Evaluation of the Alere™ i Influenza A & B 2 Assay. 2018 ASM Clinical Virology Symposium, West Palm Beach, FL. Poster.
3. ID NOW™ Strep A 2 clinical trial data, held on file.
4. Abbott Press Release: Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results.
5. Barenfager J, et al. Clinical and Financial Benefits of Rapid Detection of Respiratory Viruses: an Outcomes Study. J Clin Microbiol. 2000;38(8):2824-2828.
6. Mills JM, et al. Rapid testing for respiratory syncytial virus in a paediatric emergency department: benefits for infection control and bed management. Journal of Hospital Infection. 2011;77:248-251.
7. Tai-Seale M, et al. Time Allocation in Primary Care Office Visits. Health Serv Res. 2007;42(5):1871-1894.
8. ID NOW™ Strep A 2 Product Insert.
9. Mackie PLK, et al. Evaluation of an acute point-of-care system screening for respiratory syncytial virus infection. Journal of Hospital Infection. 2001;48(1):66-71.
10. Chartrand C, et al. Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis. J Clin Microbiol. 2015;53(12):3738-3749.
11. Bonner AB, et al. Impact of the Rapid Diagnosis of Influenza on Physician Decision-Making and Patient Management in the Pediatric ED: Results of a Randomized, Prospective, Controlled Trial. Pediatrics. 2003;112(2):363-367. 
12. Chartrand C, et al, Accuracy of Rapid Influenza Diagnostic Tests A Meta-analysis. Ann Intern Med. 2012;156(7);500-511.
13. ID NOW™ RSV Product Insert.
14. Cohen JF, et al. Rapid antigen detection test for group A streptococcus in children with pharyngitis. Cochrane Database Syst Rev. 2016,7(7):CD010502.

Contact us

©2021 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.  Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. WEBCODE-1591 03/21.